Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LY2140023: Phase II data

In a double-blind, Russian Phase II trial in 196 patients, 40 mg of LY2140023 twice daily met the primary

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE